Tango Therapeutics and Erasca Begin Combination Clinical Trial
Tango Therapeutics and Erasca have initiated a clinical trial evaluating the combination of vopimetostat and ERAS-0015 in patients with specific cancer types.
Stocks · News reference
Erasca Faces Patent Infringement Allegations Regarding ERAS-0015
Erasca has received a letter from counsel for Revolution Medicines alleging that its clinical-stage candidate, ERAS-0015, infringes on U.S. Patent No. 12,409,225.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the Q3 earnings
Erasca, Inc. Announces Participation in November 2026 Investor Conferences
Erasca, Inc. announced that its management team will participate in upcoming investor conferences throughout November 2026, including the Guggenheim 3rd Annual Healthcare Innovation Conference.
Important Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Planet Fitness, Inc. (NYSE: PLNT); PROCEPT BioRobotics Corporation (NASDAQ: PRCT); and The Simply Good Foods Company (NASDAQ: SMPL): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office has launched multiple shareholder investigations into four public companies for alleged securities fraud and breach of fiduciary duties. Erasca is accused of making misleading statements about its ERAS-0015 drug candidate and failing to disclose patent infringement risks from Revolution Medicines. Planet Fitness faces allegations of false marketing claims and concealing declining customer acquisition metrics. PROCEPT BioRobotics is investigated for undisclosed discount programs that artificially inflated sales figures and created excess inventory. The Simply Good Foods Company is accused of failing to disclose operational failures and margin erosion related to its OWYN acquisition.
Erasca shares are trading lower after the company announced it is streamlining its leadership structure, resulting in the departure of Chief Operating Officer Nicholas Chetwyn effective November 2.
8-K filing — Erasca, Inc. (ERAS)
Filed: 2026-10-16 AccNo: 0001193125-26-423433 Size: 149 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers